EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY 4.0

Safety and immunogenicity of a bivalent Ebola virus and Sudan virus ChAdOx1 vectored vaccine in adults in the UK: an open-label, non-randomised, first-in-human, phase 1 clinical trial

Daniel Jenkin, Rebecca Makinson, Helen Sanders, Alexander Sampson, Abigail Platt, Nguyen Tran, Tanya Dinesh, Reece Mabbett, Alison Lawrie, Jack Quaddy, Ian Poulton, Eleanor Berrie und 2 weitere

The Lancet Microbe · 2025

DOI: 10.1016/j.lanmic.2024.101022 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift The Lancet Microbe, 2025. Verfasst von Daniel Jenkin und 13 weiteren Autor:innen. Beteiligte Einrichtung: Jenner Institute, University of Oxford, Oxford, UK. Electronic address: daniel.jenkin@ndm.ox.ac.uk. Hauptthemen laut MEDLINE: Ebolavirus, Ebola Vaccines, Hemorrhagic Fever, Ebola, Viral Vaccines. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UK Research and Innovation, Innovate UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Four Orthoebolavirus species can cause Ebola disease, with Ebola virus (species Orthoebolavirus zairense ) and Sudan virus (species Orthoebolavirus sudanense ) responsible for the majority of outbreaks and cases. No vaccines have been approved against orthoebolaviruses other than Ebola virus. We aimed to evaluate the safety and immunogenicity of a non-replicating single-adenoviral vaccine (ChAdOx1 biEBOV) encoding both Ebola virus and Sudan virus glycoproteins.

Methods

In this open-label, non-randomised, first-in-human, phase 1, dose-escalation clinical trial of ChAdOx1 biEBOV, participants aged 18–55 years without clinically significant medical comorbidities or previous adenovirus vaccine exposure were recruited at a single site (Oxford, UK). Participants were non-randomly enrolled to a low-dose group (5 × 10⁹ viral particles [vp] of ChAdOx1 biEBOV), a medium-dose group (2·5 × 10 1 ⁰ vp), and a high-dose group (5 × 10 1 ⁰ vp). All doses were administered intramuscularly. After recruitment of all participants, the protocol was amended so that a subgroup from the high-dose group received a second high dose of vaccine 12 weeks after the first dose. Primary outcome measures were assessment of solicited adverse events for 7 days after vaccinations, unsolicited adverse events for 28 days after vaccinations, changes in clinical laboratory measures within 28 days after vaccination, and serious adverse events and adverse events of special interest for the study duration. Secondary outcomes were assessment of humoral and cellular immunity to Ebola virus and Sudan virus glycoprotein. This study is registered with ClinicalTrials.gov, NCT05079750.

Findings

Between Nov 11, 2021, and April 7, 2022, 40 individuals attended the trial screening visit, of whom 26 were enrolled (six in the low-dose group, six in the medium-dose group, and 14 in the high-dose group). Seven participants in the high-dose group received one vaccine dose and seven received two vaccine doses. Local solicited adverse events were reported by 17 (65%) of 26 participants after dose 1 and five (71%) of seven after dose 2. Systemic solicited adverse events were reported by 23 (88%) participants after dose 1 and five (71%) after dose 2. All solicited adverse events were mild or moderate, with no severe events reported. No serious adverse reactions were reported. Unsolicited adverse events related to vaccination were mostly mild or moderate and short-lived, such as joint pain or upper respiratory symptoms. One adverse event of special interest, thrombocytopenia, occurred transiently in one participant in the high-dose group. Rapidly resolving lymphopenia was common at the early post-vaccination timepoint. A single 5 × 10 1 ⁰ vp dose vaccination elicited seropositivity to Ebola virus in 14 (100%) participants in the high-dose group and elicited seropositivity to Sudan virus in 12 (86%) participants in the high-dose group; antibody titres were boosted in the two-dose group.

Interpretation

Our results suggest that the ChAdOx1 biEBOV vaccine was safe and well tolerated. Safety and tolerability data are consistent with other vaccines using the same vaccine backbone. A single 5 × 10 1 ⁰ vp dose of the vaccine was immunogenic, generating binding antibodies against both Ebola virus and Sudan virus glycoproteins, with antibody responses boosted in the subgroup receiving a second immunisation. Future research should focus on approaches to enhance antibody responses and to elicit neutralising antibodies to Sudan virus. Funding UK Research and Innovation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EbolavirusEbola VaccinesHemorrhagic Fever, EbolaViral VaccinesImmunogenicity, VaccineHumansAdultMaleFemaleAntibodies, ViralMiddle AgedYoung AdultAdolescentChAdOx1 nCoV-19United KingdomAntibodies, NeutralizingVaccination

Substanzen

Antibodies, ViralEbola VaccinesChAdOx1 nCoV-19Antibodies, NeutralizingViral Vaccines

Autor:innen und Institutionen

  • Jenner Institute, University of Oxford, Oxford, UK. Electronic address: daniel.jenkin@ndm.ox.ac.uk.
  • Jenner Institute, University of Oxford, Oxford, UK.
  • Oxford Vaccine Group, University of Oxford, Oxford, UK.
  • Pandemic Science Institute, University of Oxford, Oxford, UK.
  • Clinical Biomanufacturing Facility, University of Oxford, Oxford, UK.
  • Oxford Vaccine Group, University of Oxford, Oxford, UK; Chinese Academy of Medical Science Oxford Institute, University of Oxford, Oxford, UK.

Förderung

  • UK Research and Innovation
  • Innovate UK

Zitieren

APA

Jenkin, D., Makinson, R., Sanders, H., Sampson, A., Platt, A., Tran, N., Dinesh, T., Mabbett, R., Lawrie, A., Quaddy, J., Poulton, I., Berrie, E., Cicconi, P., & Lambe, T. (2025). Safety and immunogenicity of a bivalent Ebola virus and Sudan virus ChAdOx1 vectored vaccine in adults in the UK: an open-label, non-randomised, first-in-human, phase 1 clinical trial. The Lancet Microbe. https://doi.org/10.1016/j.lanmic.2024.101022

Vancouver

Jenkin D, Makinson R, Sanders H, Sampson A, Platt A, Tran N, et al. Safety and immunogenicity of a bivalent Ebola virus and Sudan virus ChAdOx1 vectored vaccine in adults in the UK: an open-label, non-randomised, first-in-human, phase 1 clinical trial. The Lancet Microbe. 2025. doi:10.1016/j.lanmic.2024.101022

BibTeX
@article{Jenkin2025,
  author = {Jenkin, Daniel and Makinson, Rebecca and Sanders, Helen and Sampson, Alexander and Platt, Abigail and Tran, Nguyen and Dinesh, Tanya and Mabbett, Reece and Lawrie, Alison and Quaddy, Jack and Poulton, Ian and Berrie, Eleanor and Cicconi, Paola and Lambe, Teresa},
  title = {Safety and immunogenicity of a bivalent Ebola virus and Sudan virus ChAdOx1 vectored vaccine in adults in the UK: an open-label, non-randomised, first-in-human, phase 1 clinical trial},
  journal = {The Lancet Microbe},
  year = {2025},
  doi = {10.1016/j.lanmic.2024.101022}
}
Kostenlos starten →